Starling Oncology Institute, Inc. Common Stock
STLN
38 hedge funds and large institutions have $7.66M invested in Starling Oncology Institute, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 4 increasing their positions, 18 reducing their positions, and 15 closing their positions.
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
3% less funds holding
Funds holding: 39 → 38 (-1)
10.99% less ownership
Funds ownership: 29.46% → 18.47% (-11%)
50% less capital invested
Capital invested by funds: $15.3M → $7.66M (-$7.69M)
78% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAIC
Josh Arnold Investment Consultant
Edina,
Minnesota
|
+$498K |
| 2 |
Millennium Management
New York
|
+$107K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$91.7K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$73.5K |
| 5 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$67.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.83M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$497K |
| 3 |
BlackRock
New York
|
-$410K |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$216K |
| 5 |
State Street
Boston,
Massachusetts
|
-$184K |
STLN Hedge Fund Activity: Q2 2023 in Review
38 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Institute, Inc. Common Stock (STLN) for Q2 2023, worth a combined $7.66M — down 50% from $15.3M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of STLN and 14 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 4 added.
The largest buyer was Josh Arnold Investment Consultant, adding an estimated $498K. The largest seller was Fidelity Investments, cutting an estimated $3.83M.
- 38 institutional investors held Starling Oncology Institute, Inc. Common Stock (STLN) as of Q2 2023, down from 39 in Q1 2023.
- Funds reported $7.66M of Starling Oncology Institute, Inc. Common Stock stock for Q2 2023, down 50% quarter-over-quarter.
- 14 funds opened new Starling Oncology Institute, Inc. Common Stock positions in Q2 2023 and 15 closed out, a net change of -1 holder.
- The largest Starling Oncology Institute, Inc. Common Stock buyer in Q2 2023 was Josh Arnold Investment Consultant, an estimated $498K added.
- The largest Starling Oncology Institute, Inc. Common Stock seller in Q2 2023 was Fidelity Investments, an estimated $3.83M sold.
Based on aggregated 13F filings for Q2 2023.